leisure time -WSS

leisure time

author：Wikipedia 2025-10-04 04:00:19 - browse：354

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： With Roe v Wade overturned, abortion providers work to adapt

Wikipedia

WSS

Ascension's ugly legal battle over care for poor patients in Texas

WHO recommends second malaria vaccine

Medicare Advantage overpayments discussion gets experts fired up

Health insurers' Q3 question: how much care are people getting?

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

hotspot

leisure time

Wikipedia

At least 13 dead in Texas as scorching temps continue

The biotech scorecard for Q4: 16 stock

23andMe had bad news about my health. I wish a person had delivered it

Merck to acquire Harpoon Therapeutics for $680 million

Alkermes shareholders re

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Jerome Adams on the need for new antivirals for Covid

Medicare innovation center doesn’t save money, experts say

How one medical school became remarkably diverse

IVG is promising — but it won’t replace IVF quite yet

hotspot

American taxpayers paid $1.8 trillion in health care costs in 2022

The United States is paying nearly triple for new Covid vaccines

Profiling embryos to choose those with higher IQs is almost a reality

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Merck to acquire Harpoon Therapeutics for $680 million

The stability of $0 premiums in Medicare Advantage

explore

Wikipedia

Wikipedia

knowledge